- Home
- CYBN
CYBN
Cybin Inc.
as 03-31-2025 4:00pm EST
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.
| Founded: | 2019 | Country: | Canada |
| Employees: | N/A | City: | N/A |
| Market Cap: | 153.7M | IPO Year: | N/A |
| Target Price: | $86.00 | AVG Volume (30 days): | 157.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.20 - $17.86 | Next Earning Date: | 02-11-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Cybin Inc. News
CYBN Breaking Stock News: Dive into CYBN Ticker-Specific Updates for Smart Investing
TipRanks
9 days ago
Psychedelic: Exclusive talk with biotech company Clearmind Medicine
TipRanks
10 days ago
Psychedelic: atai Life Sciences, NRx report quarterly results
TipRanks
17 days ago
Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial
Zacks
a month ago
Cybin Inc. (CYBN) Loses -25.81% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
TipRanks
a month ago
Psychedelic: GH Research, Compass Pathways report earnings results
Zacks
a month ago
Wall Street Analysts Think Cybin Inc. (CYBN) Could Surge 988.67%: Read This Before Placing a Bet
Business Wire
2 months ago
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
Zacks
2 months ago
Wall Street Analysts Believe Cybin Inc. (CYBN) Could Rally 952.23%: Here's is How to Trade
Compare CYBN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CYBN Cybin Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.